Concept Creation

The creation of concepts is based on pre-established template including all the necessary attribute pairs so that the description logic is respected. The concept creation process for the six classes of Phase 1 begins with the creation of the "Trade clinical drug" class concept. Subsequently, the "parent" concepts (in this case, the "Virtual clinical drug" concept and the "Trade Medicinal product form" concept) are created only if they do not already exist, and so on up to the concepts for the "Virtual medicinal product" and "Trade medicinal product" classes. Details regarding the model template and the descriptions template for each of the classes are detailed in the following pages.

Concept Descriptions

The creation of the descriptions for all classes is automated following pre-established rules. The concepts from the Substance and Pharmaceutical dose form hierarchies are used to construct these descriptions, therefore the descriptions of these basic concepts are carefully revised so that the Canadian preferred terms accurately reflect the terms used in Canada. Also, the following general rules are applied to these descriptions.

• The FSN and PT of the concepts are constructed using respectively the en-CA and fr-CA FSNs and the en-CA and fr-CA preferred terms of their basic components.
• For substances, if new concepts are required, the FSN is created based on WHO International Nonproprietary Names (INN) to align with International content. The preferred term is always aligned with the Canadian preference.
• Product name and Supplier are always capitalized, and no changes are made to the source data.
• Manufactured dose forms is coming from DPD and not from the product monograph.

Note: A more comprehensive and elaborated editorial guide to the CMT data model is currently being written and will be shared soon.